Publication

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group

Journal Paper/Review - Jul 5, 2011

Units
PubMed
Doi

Citation
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
Type
Journal Paper/Review (English)
Journal
Gynecol Oncol 2011; 123
Publication Date
Jul 5, 2011
Issn Electronic
1095-6859
Pages
27-32
Brief description/objective

The aim of this study was to select the best catumaxomab regimen for further investigation in ovarian cancer based on confirmed tumour response.